BC Innovations | Nov 15, 2019
Product Development

Minerva on the verge in neuropsychiatry with two compounds close to verdict

Minerva Neurosciences is on the precipice of two clinical readouts that could determine whether its founding bet on a pair of neuropsychiatry compounds from Mitsubishi Tanabe has panned out. Neither molecule represents a shift from...
BC Extra | May 7, 2019
Clinical News

May 7 Clinical Quick Takes: AZ, Merck, Osmotica, AlzeCure

AZ's Calquence meets in Phase III for CLL  AstraZeneca plc (LSE:AZN; NYSE:AZN) said an interim analysis of the Phase III ASCEND trial to treat relapsed or refractory chronic lymphocytic leukemia showed that Calquence acalabrutinib as...
BC Week In Review | Feb 7, 2019
Company News

Heptares, Medicxi spin out narcolepsy companies

The Heptares Therapeutics Ltd. unit of Sosei Group Corp. (Tokyo:4565) partnered with life sciences VC Medicxi Ventures to spin out two asset-centric newcos, Orexia Ltd. and Inexia Ltd., to develop preclinical orexin agonists to treat...
BC Extra | Feb 4, 2019
Company News

Heptares, Medicxi spin out narcolepsy companies

The Heptares Therapeutics Ltd. unit of Sosei Group Corp. (Tokyo:4565) partnered with life sciences VC Medicxi Ventures to spin out two asset-centric newcos, Orexia Ltd. and Inexia Ltd., to develop preclinical orexin agonists to treat...
BC Extra | Jul 28, 2017
Clinical News

Idorsia insomnia candidate headed for Phase III

Idorsia Ltd. (SIX:IDIA) said ACT-541468 led to a significant, dose-dependent reduction in Wake After Sleep Onset (WASO) from baseline on the first two nights of treatment in a pair of Phase II trials to treat...
BC Innovations | Oct 15, 2015
Distillery Therapeutics

Therapeutics: Orexin 2 receptor (OX2R; HCRTR2)

Neurology INDICATION: Cataplexy; narcolepsy Cell culture and mouse studies identified an OX2R activator that could help treat cataplexy and narcolepsy. Screening of a small molecule library in a mammalian cell-based assay of OX2R-mediated calcium signaling...
BioCentury | Aug 17, 2015
Product Development

Structure knows best

Although most of Heptares' compounds are against clinically validated targets, and only one currently boasts first-in-class potential, the structure-based drug design company is building a case for its ability to expand targets into new indications,...
BC Week In Review | Feb 16, 2015
Company News

Merck sales and marketing update

Merck launched Belsomra suvorexant in the U.S. to treat adults with insomnia. The dual orexin receptor antagonist is available in 5, 10, 15 and 20 mg oral tablets with a wholesale acquisition cost (WAC) of...
BC Innovations | Feb 12, 2015
Distillery Therapeutics

Therapeutics: Orexin 1 receptor (HCRTR1; OX1R)

Neurology INDICATION: Panic Rat studies suggest a brain-penetrating OX1R antagonist could help treat stress- and hyperarousal-associated psychiatric disorders such as panic. Previous chemical synthesis and in vitro testing identified an antagonist that selectively bound human...
BioCentury | Jan 12, 2015
Finance

Buyside view XXIII: Milestones galore

Stephen Hansen, Associate Editor and Jennifer Rhodes, Staff Writer   Buyside view XXIII The maturation of the biotech sector over the past few years finds fund managers focusing on a slew of clinical milestones and...
Items per page:
1 - 10 of 38